News | September 12, 2012

CircuLite Receives CE Mark Approval for Synergy Miniature VAD System

Circulatory support system creates a new paradigm for early treatment of heart failure

CircuLite Synenery Circulatory Support System VAD

CircuLite Inc. announced that it has received CE Marking approval for the Synergy Circulatory Support System, a micro-pump designed to halt the progression of heart failure. By working with the heart’s native pumping capacity, Synergy is specifically targeted for treatment of ambulatory heart failure patients (INTERMACS 4,5,6 / NYHA IIIB and early IV) who remain symptomatic despite standard medical management.

Synergy is approximately the size of a AA battery and is implanted superficially in a pacemaker-like pocket under the right collarbone. Synergy is approximately 90 percent lighter than existing ventricular assist devices (VADs), and unlike VADs, implantation of Synergy is faster and does not require an open-chest procedure or cardiopulmonary bypass.

CE marking approval was based on positive clinical results from 44 patients in an ongoing, multi-center European trial, recently presented at the International Society for Heart and Lung Transplantation (ISHLT) meeting. A total of 59 patients have been implanted with the Synergy System in the CE mark trial at nine European centers.

“There is currently a gap in the treatment of heart failure, with no satisfactory options available for patients who are not responding to standard medical therapy. Synergy, with its small size, minimally invasive procedure and relatively fast procedure time, is ideally suited for these patients,” said Bart Meyns, M.D., Ph.D., professor and chief of cardiac surgery at Gasthuisberg University Hospital and principal investigator of CircuLite’s clinical study. “In my experience with this technology, the results have been remarkable. Patients typically recover from the procedure quickly and are soon after able to perform many activities that they could not do before. This technology allows me to provide a new treatment strategy for a large number of patients who previously had no definitive options.”

“The European approval of Synergy is a significant milestone both for CircuLite and, more broadly, for the treatment of heart failure,” said Paul Southworth, president and chief executive officer of CircuLite. “Synergy changes the paradigm of heart failure treatment for those who are not responding to standard medical management by working as a complement to the heart’s function. The benefits are multifaceted—patients feel better, recover rapidly and are discharged quickly—which provides the potential for a cost reduction impact for hospitals. With CE marking in place, we will begin a controlled launch of this groundbreaking advancement in select European markets.”

For more information: www.circulite.net/products-technology/about-synergy.php

Related Content

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery | May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Overlay Init